{"denomUnitsSelected":"Participants","description":"TFFS is defined as the time start from the first day of study therapy until discontinuation for any reason, including disease progression, toxicity, or death.\n\nProgressive disease: Serum M-protein: absolute increase must be ≥ 0.5 g/dL, ≥ 1 g/dL if the lowest M component was ≥ 5 g/dL; absolute Urine M-protein increase≥ 200 mg/24 h). In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels must be \\> 10 mg/dL; without measurable involved FLC levels, bone marrow plasma cell percentage irrespective of baseline status Appearance of a new lesion(s), ≥ 50% increase from nadir \\> 1 lesion, or ≥ 50% increase in the longest diameter of a previous lesion \\>1 cm in short axis;≥ 50% increase e in circulating plasma cells (minimum of 200 cells per μL) if this is the only measure of disease.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years","title":"Treatment Failure-free Survival (TFFS)","type":"SECONDARY"}